Analyst Price Targets — TGTX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 15, 2026 12:51 am | — | Goldman Sachs | $39.00 | $29.54 | TheFly | TG Therapeutics price target raised to $39 from $37 at Goldman Sachs |
| October 6, 2025 10:11 am | Emily Bodnar | H.C. Wainwright | $60.00 | $36.71 | TheFly | TG Therapeutics assumed with a Buy at H.C. Wainwright |
| November 5, 2024 11:41 am | Edward White | H.C. Wainwright | $27.50 | $12.93 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $55 at H.C. Wainwright |
| August 6, 2024 6:02 pm | Corinne Jenkins | Goldman Sachs | $20.00 | $20.58 | TheFly | TG Therapeutics price target raised to $20 from $18 at Goldman Sachs |
| May 3, 2024 6:46 am | Edward White | H.C. Wainwright | $24.50 | $8.21 | StreetInsider | TG Therapeutics (TGTX) PT Raised to $49 at H.C. Wainwright |
| February 7, 2023 7:34 am | — | Cantor Fitzgerald | $24.00 | $18.48 | Benzinga | Cantor Fitzgerald Maintains Overweight on TG Therapeutics, Raises Price Target to $24 |
| December 30, 2022 9:21 am | — | Evercore ISI | $16.00 | $11.83 | Benzinga | Evercore ISI Group Maintains Outperform on TG Therapeutics, Raises Price Target to $16 |
| December 29, 2022 6:10 am | Edward White | H.C. Wainwright | $12.00 | $4.23 | TheFly | TG Therapeutics price target raised to $24 from $19 at H.C. Wainwright |
| April 19, 2022 10:24 am | — | Goldman Sachs | $5.00 | $7.26 | Benzinga | Goldman Sachs Maintains Sell on TG Therapeutics, Lowers Price Target to $5 |
| April 18, 2022 12:00 am | Mayank Mamtani | Telsey Advisory | $11.50 | $3.46 | TipRanks Contributor | Has TG Therapeutics Stock Hit Bottom? Looking for the Silver Lining |
Latest News for TGTX
TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version's trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets.
TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.
Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 months Top-line data expected year-end 2026/ first quarter 2027 NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company's anti-CD20 monoclonal antibody, in people…
Briumvi's US net product revenues reached $182.7M in Q4'25, with 19.5% sequential growth, and 2026 global revenue guidance is $875M–$900M. Key catalysts include the ENHANCE trial readout (mid-2026) and pivotal subcutaneous Briumvi data (year-end 2026/1Q 2027), both with significant upside potential. TGTX's $300M buyback program could provide downside support, although material negative updates are still a risk even…
JPMorgan Chase and Co. raised its holdings in TG Therapeutics, Inc. (NASDAQ: TGTX) by 56.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 227,934 shares of the biopharmaceutical company's stock after buying an additional 81,907 shares during the quarter. JPMorgan Chase and
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TGTX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.